In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS


18F-FDG PET/CT improves diagnostic certainty in native and prosthetic valve infective endocarditis over the modified Duke's criteria

Session Moderated Posters 3

Speaker Christopher Peter Primus

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Positron Emission Tomography (PET)
  • Session type : Moderated Posters
  • FP Number : 197

Authors : CP Primus (London,GB), T Clay (London,GB), A Al-Khayfawee (London,GB), PR Scully (London,GB), K Wong (London,GB), R Uppal (London,GB), S Das (London,GB), R Serafino-Wani (London,GB), S Bhattacharyya (London,GB), LC Davies (London,GB), S Woldman (London,GB), L Menezes (London,GB)

CP Primus1 , T Clay2 , A Al-Khayfawee3 , PR Scully2 , K Wong4 , R Uppal1 , S Das1 , R Serafino-Wani4 , S Bhattacharyya4 , LC Davies1 , S Woldman1 , L Menezes4 , 1Barts Heart Centre & Queen Mary, University of London - London - United Kingdom of Great Britain & Northern Ireland , 2University College London - London - United Kingdom of Great Britain & Northern Ireland , 3University College London Hospitals - London - United Kingdom of Great Britain & Northern Ireland , 4Barts Heart Centre - London - United Kingdom of Great Britain & Northern Ireland ,


ESC Infective Endocarditis (IE) Guidance (2015) recognises the shortcomings of the modified Duke’s criteria in cases where transoesophageal echocardiography remains equivocal despite high index of suspicion. 18F-FDG PET/CT (PET) can be helpful, based on class C evidence. We explored the role for PET to improve diagnostic certainty in both native (NVE) and prosthetic valve endocarditis (PVE).

Dual centre retrospective study of patients with suspected IE undergoing PET (01/2010 to date); patients with implantable cardiac device infection were excluded. Myocardial suppression technique was used in all cases, and studies were assessed for the pattern/distribution of tracer uptake. Patients were classified as confirmed/probable/rejected IE pre- and post-PET, with incremental benefit assessed vs actual diagnosis. This was defined by surgical specimen or Endocarditis Team consensus at up to 3-months following index admission. PET diagnostic performance was assessed by Receiver Operating Characteristic (ROC) analysis and Net Reclassification Index (NRI).

PET was performed in 69 patients; 32 for NVE and 37 for PVE (male=56; mean age 61.4y; range 19–89y). Myocardial suppression failed in 3 cases. 16/69 (23%) cases were culture negative, making a pre-PET diagnosis by Duke’s criteria challenging. 22/69 (32%) patients required surgery.

PET sensitivity, specificity, positive and negative predictive values were 75%, 92%, 94% & 69% respectively in NVE, and 87%, 86%, 91% & 80% in PVE. The pattern of tracer avidity was especially important in PVE, with focal uptake suggestive of infection and diffuse uptake reflecting post-surgical change. PET accurately re-classified patients to both confirm and refute IE [NRI: NVE 0.89; PVE 0.90] (Table 1). ROC curves showed significant incremental benefit of PET over Duke’s criteria alone in both PVE (AUC 0.877 vs 0.633) and NVE (AUC 0.883 vs 0.750) (Figure 1).

PET improves diagnostic certainty when combined with modified Duke’s criteria in diagnosing both NVE and PVE.

Diagnosis by Duke's Criteria Native Valve Endocarditis Prosthetic Valve Endocarditis
Pre-PET Post-PET Discharge Diagnosis Pre-PET Post-PET Discharge Diagnosis
Definite 14 16 20 14 21 22
Probable 12 2 - 19 3 -
Rejected 6 14 12 4 13 15
Net re-classification index (NRI): NVE 0.89 (positive reclassification, NRI 0.44; negative reclassification, NRI 0.45) and PVE 0.90 (positive reclassification, NRI 0.50; negative reclassification, NRI 0.40) demonstrating the ability of PET to both successfully diagnose and refute IE.

This content is currently on FREE ACCESS


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are